However, the lack of a clinically significant benefit from FLT3-inhibitors in NUP98::NSD1/FLT3-ITD AML indicates that the NUP98 fusion is a potent leukemic driver with an independent impact on prognosis (Tarlock et al., 2019). The gene discussed is NUP98; the disease is acute myeloid leukemia.